STOCK TITAN

ARVN Form 4: Director Briggs Morrison acquires 30,000 shares at $7.57 avg

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Arvinas, Inc. director Briggs Morrison reported purchasing 30,000 shares of ARVN common stock on 09/22/2025 at a weighted average price of $7.567 per share. After the transaction, Mr. Morrison beneficially owned 76,021 shares. The filing was submitted on 09/24/2025 and signed by an attorney-in-fact.

The footnote clarifies the $7.567 figure is a weighted average for multiple purchases priced between $7.50 and $7.65; the reporting person offered to provide a breakdown of per-trade quantities on request. No derivative transactions or additional securities classes are reported on this Form 4.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: A director purchased 30,000 ARVN shares at a weighted average of $7.567, modest insider buying without derivative activity.

The reported purchase is a straightforward, non-derivative acquisition by a company director, increasing beneficial holdings to 76,021 shares. Insider buys can signal confidence, but this filing alone lacks context on timing relative to company events or the director's usual trading pattern. The weighted-average purchase and offered disclosure of per-trade quantities are consistent with compliant Form 4 reporting. No sales, options exercises, or other material changes in ownership structure are included.

TL;DR: Routine director purchase disclosed correctly; materiality to shareholders is limited absent size-relative context.

The transaction was reported timely and includes the customary explanatory footnote about price ranges, which improves transparency. As a single non-derivative purchase by a director, it does not indicate any governance change or compensation adjustment. For investors assessing insider signals, the purchase size and resulting 76,021-share holding should be compared to total outstanding shares and past insider activity, which this Form 4 does not provide.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Morrison Briggs

(Last) (First) (Middle)
C/O ARVINAS, INC.
5 SCIENCE PARK, 395 WINCHESTER AVE.

(Street)
NEW HAVEN CT 06511

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ARVINAS, INC. [ ARVN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/22/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/22/2025 P 30,000 A $7.567(1) 76,021 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The purchase price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.50 to $7.65, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
Remarks:
/s/ Christina Bailey, as attorney-in-fact for Briggs Morrison 09/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ARVN director Briggs Morrison report on Form 4?

He purchased 30,000 shares of ARVN common stock on 09/22/2025 at a weighted average price of $7.567, increasing beneficial ownership to 76,021 shares.

When was the Form 4 for ARVN filed and who signed it?

Filed 09/24/2025 and signed by Christina Bailey as attorney-in-fact for Briggs Morrison.

Does the Form 4 report any derivative transactions for ARVN?

No. Table II shows no derivative securities acquired, disposed of, or beneficially owned in this filing.

What does the $7.567 price represent on the ARVN Form 4?

It is a weighted-average purchase price for multiple transactions executed between $7.50 and $7.65; detailed per-trade quantities are available on request.

How many shares does Briggs Morrison own after the reported transaction?

76,021 shares of ARVN common stock following the 30,000-share purchase.
Arvinas

NASDAQ:ARVN

ARVN Rankings

ARVN Latest News

ARVN Latest SEC Filings

ARVN Stock Data

797.02M
59.11M
6.85%
94.18%
11.67%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW HAVEN